Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of PF-04634817 versus ranibizumab in adult patients with diabetic macular edema
2013-003147-27Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic macular edema (DME) comparing PF-04634817 arm, Ranibizumab arm and Placebo arm (3 arms). Primary endpoint: Mean letter change from baseline at Week 12 in best corrected visual acuity. Started Nov 2013; status: completed.
02
Drugs
PF-04634817ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2013-003147-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003147-27.